tirzepatide surmount-1 weight loss percent 72 weeks results for Obesity: Highlights from the Trial Lilly released results for SURMOUNT-2,

This site provides good subcutaneous tissue depth and is easily accessible for self-injection

With commercial supply now stabilized, the FDA has ended its shortage-related enforcement discretion, significantly narrowing the circumstances under which compounded tirzepatide may be legally prescribed

Tirzepatide achieved up to 22.5% in its 72-week Phase 3 SURMOUNT-1 trial

Contact your healthcare provider for guidance and follow the FDA-labeled missed-dose instructions, which typically advise administering the missed dose within 4 days or skipping to the next scheduled dose

Food and Drug Administration (FDA) for the treatment of obesity

Most people take their last semaglutide dose, wait one week, then start tirzepatide at an appropriate dose based on their previous semaglutide level